Olaratumab

DRUG19 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Eli Lilly and Company, University of Miami, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Conditions

Adult Glioblastoma MultiformeAdvanced Soft Tissue SarcomaGastrointestinal Stromal Tumor (GIST)LeiomyosarcomaMalignancyMetastasisMetastatic Pancreatic CancerNeoplasm

Phase 1

A Study of Olaratumab in Soft Tissue Sarcoma

CompletedNCT01185964

Eli Lilly and CompanySarcoma, Soft Tissue

Start: 2010-10-31End: 2016-04-30Updated: 2017-04-14

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

CompletedNCT01199822

Eli Lilly and CompanyMalignancy, Metastasis

Start: 2010-09-30End: 2012-01-31Updated: 2017-04-14

A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

CompletedNCT02326025

Eli Lilly and CompanySarcoma, Soft Tissue

Start: 2015-01-22End: 2018-11-02Updated: 2019-11-21

A Study of Olaratumab in Japanese Participants With Advanced Cancer

CompletedNCT02377752

Eli Lilly and CompanyNeoplasm

Start: 2015-03-23End: 2020-01-14Updated: 2021-02-17

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

CompletedNCT02659020

Eli Lilly and CompanySoft Tissue Sarcoma

Start: 2016-03-01End: 2021-04-27Updated: 2022-05-09

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

CompletedNCT02677116

Eli Lilly and CompanyNeoplasm Metastasis

Start: 2016-08-29End: 2019-04-03Updated: 2020-05-20

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

CompletedNCT02783599

Eli Lilly and CompanySoft Tissue Sarcoma

Start: 2016-10-11End: 2018-07-05Updated: 2019-08-12

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

CompletedNCT03086369

Eli Lilly and CompanyMetastatic Pancreatic Cancer

Start: 2017-06-22End: 2021-06-17Updated: 2022-06-28

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

CompletedNCT03126591

Eli Lilly and CompanySoft Tissue Sarcoma

Start: 2017-07-03End: 2023-02-21Updated: 2024-10-23

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

CompletedNCT03283696

Eli Lilly and CompanySoft Tissue Sarcoma

Start: 2017-10-18End: 2019-08-25Updated: 2020-09-10

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

WithdrawnNCT03437070

University of MiamiLeiomyosarcoma

Start: 2019-06-30End: 2023-06-30Updated: 2019-03-18

Phase 2

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

CompletedNCT00895180

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAdult Glioblastoma Multiforme

Start: 2010-07-31End: 2014-03-04Updated: 2017-12-27

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

CompletedNCT00913835

Eli Lilly and CompanyOvarian Neoplasms

Start: 2009-06-30End: 2014-02-28Updated: 2019-09-26

A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00918203

Eli Lilly and CompanyNon-Small Cell Lung Cancer

Start: 2010-01-31End: 2017-11-17Updated: 2019-01-10

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

CompletedNCT01204710

Eli Lilly and CompanyProstate Cancer

Start: 2010-10-31End: 2013-10-31Updated: 2019-09-20

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

TerminatedNCT01316263

Eli Lilly and CompanyGastrointestinal Stromal Tumor (GIST)

Start: 2011-08-31End: 2012-11-30Updated: 2017-03-09

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

TerminatedNCT03698227

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAdvanced Soft Tissue Sarcoma

Start: 2018-11-12End: 2020-06-25Updated: 2020-07-15

Phase 3

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

CompletedNCT02451943

Eli Lilly and CompanySoft Tissue Sarcoma

Start: 2015-09-14End: 2024-06-27Updated: 2025-07-15

Unknown Phase

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Eli Lilly and CompanySoft Tissue Sarcoma

Updated: 2024-12-16

Related Papers

Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).

Journal of Clinical Oncology2021-05-209 citations

Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

Clinical Cancer Research2021-02-2543 citations

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

JAMA2020-04-07288 citations

5PSQ-045 Olaratumab: what is the economic impact on the national health system?

Section 5: Patient safety and quality assurance2020-03-01

Antibodies to watch in 2020.

2020-01-01328 citations

Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.

2019-07-225 citations

Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin

Cancer Research2019-07-01

Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin

Clinical Trials2019-07-01

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

Journal of Clinical Oncology2019-06-0564 citations

Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma: Data of real-world utilization in Austria.

Journal of Clinical Oncology2019-05-202 citations

No relevant activity of olaratumab in patient-derived soft tissue sarcoma xenografts selected for expression of platelet-derived growth factor receptor a.

Journal of Clinical Oncology2019-05-20

A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.

Journal of Clinical Oncology2019-01-293 citations

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BMC Cancer2018-12-0132 citations

Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.

Journal of Clinical Oncology2018-05-202 citations

Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.

Journal of Clinical Oncology2018-05-201 citations

Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.

2018-02-1610 citations

A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.

Journal of Clinical Oncology2018-02-011 citations

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

2017-07-1810 citations

A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.

Journal of Clinical Oncology2017-05-20

Olaratumab for advanced soft tissue sarcoma.

2017-05-0511 citations

5 more papers not shown